undamentalytics Newsletter
Sign in

Novocure Ltd cash flow statement

In fiscal 2025, Novocure Ltd's operations generated −$49.0m of cash; it spent $26.6m on capital projects, leaving free cash flow of −$75.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−53−74−100−108−33−227998331−73−26−49−1
Depreciation and amortisation12368989101111111517
Stock-based pay5512222740527695107116160105117
Capital spending2156771015242127432724
Free cash flow−55−75−105−113−41−91684599−100−69−76−25
Free cash flow after stock pay−60−80−116−135−68−48−368−36−98−216−229−181−142
Dividends paid——000—————————
Share buybacks——0———————————
Shares issued192225212223554444

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: GKOS vs NVCRNVCR vs TMDXMYGN vs NVCR

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Novocure Ltd's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Novocure Ltd.